PP-106. Total antioxidant capacity and total oxidant status in preterm infants with respiratory distress syndrome

2010 ◽  
Vol 86 ◽  
pp. S60
Author(s):  
Evrim Alyamac Dizdar ◽  
Nurdan Uras ◽  
Suna Oguz ◽  
Omer Erdeve ◽  
Fatma Nur Sari ◽  
...  
Keyword(s):  
Respiratory Distress Syndrome ◽  
Respiratory Distress ◽  
Antioxidant Capacity ◽  
Preterm Infants ◽  
Total Antioxidant Capacity ◽  
Distress Syndrome ◽  
Total Oxidant Status ◽  
Total Antioxidant ◽  
Oxidant Status

scholarly journals PS-211a Total Oxidant Status And Total Antioxidant Capacity In Amniotic Fluid Of Late Preterm Infants

2014 ◽  
Vol 99 (Suppl 2) ◽  
pp. A189.1-A189 ◽  
Author(s):  
I Mungan Akin ◽  
MS Yanartas ◽  
S Sevuk Ozumut ◽  
B Isbilen ◽  
D Buyukkayhan ◽  
...  
Keyword(s):  
Amniotic Fluid ◽  
Antioxidant Capacity ◽  
Preterm Infants ◽  
Total Antioxidant Capacity ◽  
Late Preterm ◽  
Total Oxidant Status ◽  
Late Preterm Infants ◽  
Total Antioxidant ◽  
Oxidant Status

scholarly journals Does ibuprofen treatment in patent ductus arteriosus alter oxygen free radicals in premature infants?

2016 ◽  
Vol 27 (3) ◽  
pp. 507-511 ◽  
Author(s):  
Melek Akar ◽  
Tulin G. Yildirim ◽  
Gonca Sandal ◽  
Senol Bozdag ◽  
Omer Erdeve ◽  
...  
Keyword(s):  
Patent Ductus Arteriosus ◽  
Antioxidant Capacity ◽  
Preterm Infants ◽  
Total Antioxidant Capacity ◽  
Ductus Arteriosus ◽  
Total Oxidant Status ◽  
Total Antioxidant ◽  
Oral Ibuprofen ◽  
Oxidant Status ◽  
Patent Ductus

AbstractIntroductionIbuprofen is used widely to close patent ductus arteriosus in preterm infants. The anti-inflammatory activity of ibuprofen may also be partly due to its ability to scavenge reactive oxygen species and reactive nitrogen species. We evaluated the interaction between oxidative status and the medical treatment of patent ductus arteriosus with two forms of ibuprofen.Materials and methodsThis study enrolled newborns of gestational age ⩽32 weeks, birth weight ⩽1500 g, and postnatal age 48–96 hours, who received either intravenous or oral ibuprofen to treat patent ductus arteriosus. Venous blood was sampled before ibuprofen treatment from each patient to determine antioxidant and oxidant concentrations. Secondary samples were collected 24 hours after the end of the treatment. Total oxidant status and total antioxidant capacity were measured using Erel’s method.ResultsThis prospective randomised study enrolled 102 preterm infants with patent ductus arteriosus. The patent ductus arteriosus closure rate was significantly higher in the oral ibuprofen group (84.6 versus 62%) after the first course of treatment (p=0.011). No significant difference was found between the pre- and post-treatment total oxidant status and total antioxidant capacity in the groups.DiscussionIbuprofen treatment does not change the total oxidant status or total antioxidant capacity. We believe that the effect of ibuprofen treatment in inducing ischaemia overcomes the scavenging effect of ibuprofen.

Total oxidant status and total antioxidant capacity in the saliva of patients with chronic periodontitis

MedPharmRes ◽  
2020 ◽  
Vol 4 (4) ◽  
pp. 21-26
Author(s):  
Thuy T. Nguyen ◽  
Duc A. Vo ◽  
Truc Thanh Thai ◽  
Thuy L. Vo ◽  
Nam C-N. Huynh
Keyword(s):  
Antioxidant Capacity ◽  
Chronic Periodontitis ◽  
Total Antioxidant Capacity ◽  
Control Group ◽  
Total Oxidant Status ◽  
Oxidative Stress Biomarkers ◽  
Clinical Attachment Loss ◽  
Attachment Loss ◽  
Total Antioxidant ◽  
Oxidant Status

Background: Recently, methods of quantifying total oxidant status (TOS) and total antioxidant capacity (TAOC) were developed to investigate periodontitis. This study was performed to evaluate the salivary TOS and TAOC levels of patients with chronic periodontitis (CP) and investigating the association between periodontal clinical parameters and these oxidative stress biomarkers. Material and methods: 40 participants (23-65 years old) were classified into two groups of 20 each, namely the CP group (participants with CP) and the control group (periodontally healthy controls). Clinical periodontal parameters were monitored, and TOS and TAOC levels were measured using laboratory assays. Results: TOS level increased in the saliva of patients with CP and the salivary TAOC in patients with CP was significantly lower than that of the control group. The TOS had a positive moderate correlation with the plaque index and clinical attachment loss (r=0.32 and 0.37, respectively) while TAOC was negatively and moderately correlated with clinical attachment loss (r=-0.35). Conclusion: Salivary TOS and TAOC were distinguished in healthy and chronic PD patients. Further studies are required to comprehensively evaluate the potential role of these biomarkers in diagnosis and treatment evaluation of CP.

Sign in / Sign up

Export Citation Format

Share Document